Log in
NASDAQ:ILMN

Illumina Stock Forecast, Price & News

$292.70
-22.20 (-7.05 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$288.01
Now: $292.70
$311.77
50-Day Range
$268.51
MA: $318.44
$353.65
52-Week Range
$196.78
Now: $292.70
$404.20
Volume2.73 million shs
Average Volume1.29 million shs
Market Capitalization$42.73 billion
P/E Ratio62.54
Dividend YieldN/A
Beta0.9
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Read More
Illumina logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.71 out of 5 stars

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:ILMN
CUSIP45232710
Phone858-202-4500
Employees7,700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.54 billion
Cash Flow$7.50 per share
Book Value$31.38 per share

Profitability

Net Income$1.00 billion

Miscellaneous

Market Cap$42.73 billion
Next Earnings Date2/3/2021 (Estimated)
OptionableOptionable
$292.70
-22.20 (-7.05 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ILMN News and Ratings via Email

Sign-up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Illumina (NASDAQ:ILMN) Frequently Asked Questions

How has Illumina's stock price been impacted by COVID-19?

Illumina's stock was trading at $246.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ILMN shares have increased by 19.0% and is now trading at $292.70.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Illumina?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 3 sell ratings, 9 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Illumina
.

When is Illumina's next earnings date?

Illumina is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Illumina
.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) issued its quarterly earnings data on Thursday, October, 29th. The life sciences company reported $1.02 EPS for the quarter, beating the Zacks' consensus estimate of $0.77 by $0.25. The life sciences company had revenue of $794 million for the quarter, compared to analysts' expectations of $713.97 million. Illumina had a net margin of 20.67% and a return on equity of 19.13%. The business's revenue for the quarter was down 12.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.93 earnings per share.
View Illumina's earnings history
.

What price target have analysts set for ILMN?

17 brokerages have issued 12 month price objectives for Illumina's shares. Their forecasts range from $280.00 to $400.00. On average, they expect Illumina's stock price to reach $323.59 in the next year. This suggests a possible upside of 10.6% from the stock's current price.
View analysts' price targets for Illumina
.

Are investors shorting Illumina?

Illumina saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 4,820,000 shares, an increase of 23.3% from the September 30th total of 3,910,000 shares. Based on an average trading volume of 1,430,000 shares, the short-interest ratio is currently 3.4 days. Approximately 3.3% of the shares of the company are short sold.
View Illumina's Short Interest
.

Who are some of Illumina's key competitors?

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), The Walt Disney (DIS), PayPal (PYPL), salesforce.com (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

Who are Illumina's key executives?

Illumina's management team includes the following people:
  • Mr. Francis A. deSouza, CEO, Pres & Director (Age 49)
  • Mr. Sam A. Samad, CFO & Sr. VP (Age 50, Pay $626.7k)
  • Dr. Joydeep Goswami, Sr. VP of Corp. Devel. & Strategic Planning (Age 49, Pay $384.38k)
  • Ms. Aimee L. Hoyt, Chief People Officer & Sr. VP (Age 49, Pay $864.07k)
  • Mr. Robert P. Ragusa, Sr. VP of Global Quality & Operations (Age 60)

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Who are Illumina's major shareholders?

Illumina's stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (0.67%), Douglas Lane & Associates LLC (0.24%), TCW Group Inc. (0.19%), KAMES CAPITAL plc (0.12%), DAVENPORT & Co LLC (0.10%) and Waverton Investment Management Ltd (0.08%). Company insiders that own Illumina stock include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Karin Eastham, Marc Stapley, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi.
View institutional ownership trends for Illumina
.

Which major investors are selling Illumina stock?

ILMN stock was sold by a variety of institutional investors in the last quarter, including First Hawaiian Bank, Envestnet Asset Management Inc., TCW Group Inc., CIBC Private Wealth Group LLC, Gateway Investment Advisers LLC, Toronto Dominion Bank, WINTON GROUP Ltd, and Standard Life Aberdeen plc. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Sam Samad, and Susan H Tousi.
View insider buying and selling activity for Illumina
.

Which major investors are buying Illumina stock?

ILMN stock was bought by a variety of institutional investors in the last quarter, including DAVENPORT & Co LLC, DekaBank Deutsche Girozentrale, ARK Investment Management LLC, BP PLC, Bradley Foster & Sargent Inc. CT, KBC Group NV, Robeco Institutional Asset Management B.V., and Artemis Investment Management LLP.
View insider buying and selling activity for Illumina
.

How do I buy shares of Illumina?

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $292.70.

How big of a company is Illumina?

Illumina has a market capitalization of $42.73 billion and generates $3.54 billion in revenue each year. The life sciences company earns $1.00 billion in net income (profit) each year or $6.57 on an earnings per share basis. Illumina employs 7,700 workers across the globe.

What is Illumina's official website?

The official website for Illumina is www.illumina.com.

How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.